

1 Sec. 556.051. AUTHORIZATION TO ENTER AND INSPECT. The
2 board or a representative of the board may enter and inspect a
3 facility relative to the following:

4 (1) drug storage and security;

5 (2) equipment;

6 (3) components used in compounding, finished and
7 unfinished products, containers, and labeling of any item;

8 (4) sanitary conditions; or

9 (5) [~~4~~] records, reports, or other documents
10 required to be kept or made under this subtitle, Chapter 481 or 483,
11 Health and Safety Code, or the Comprehensive Drug Abuse Prevention
12 and Control Act of 1970 (21 U.S.C. Section 801 et seq.) or rules
13 adopted under one of those laws.

14 SECTION 3. Section 556.053, Occupations Code, is amended to
15 read as follows:

16 Sec. 556.053. EXTENT OF INSPECTION. Except as otherwise
17 provided in an inspection warrant, the person authorized to
18 represent the board may:

19 (1) inspect and copy documents, including records or
20 reports, required to be kept or made under this subtitle, Chapter
21 481 or 483, Health and Safety Code, or the Comprehensive Drug Abuse
22 Prevention and Control Act of 1970 (21 U.S.C. Section 801 et seq.)
23 or rules adopted under one of those laws;

24 (2) inspect, within reasonable limits and in a
25 reasonable manner, a facility's storage, equipment, security,
26 prescription drugs or devices, components used in compounding,
27 finished and unfinished products, or records; or

1 (3) perform an inventory of any stock of prescription
2 drugs or devices, components used in compounding, or finished and
3 unfinished products in a facility and obtain samples of those
4 substances.

5 SECTION 4. Subchapter D, Chapter 562, Occupations Code, is
6 amended to read as follows:

7 SUBCHAPTER D. COMPOUNDED AND PREPACKAGED DRUGS [~~ADVERTISING OR~~
8 ~~PROMOTING BY PHARMACIST OR PHARMACY~~]

9 Sec. 562.151. DEFINITIONS. In this subchapter:

10 (1) "Office use" means the provision and
11 administration of a compounded drug to a patient by a practitioner
12 in the practitioner's office or by the practitioner in a health care
13 facility or treatment setting, including a hospital, ambulatory
14 surgical center, or pharmacy in accordance with Chapter 563.

15 (2) "Prepackaging" means the act of repackaging and
16 relabeling quantities of drug products from a manufacturer's
17 original container into unit dose packaging or a multiple dose
18 container for distribution within a facility licensed as a Class C
19 pharmacy or to other pharmacies under common ownership for
20 distribution within those facilities. The term as defined does not
21 prohibit the prepackaging of drug products for use within other
22 pharmacy classes.

23 (3) "Reasonable quantity" with reference to drug
24 compounding means an amount of a drug that:

25 (A) does not exceed the amount a practitioner
26 anticipates may be used in the practitioner's office before the
27 expiration date of the drug;

1 (B) is reasonable considering the intended use of
2 the compounded drug and the nature of the practitioner's practice;
3 and

4 (C) for any practitioner and all practitioners as
5 a whole, is not greater than an amount the pharmacy is capable of
6 compounding in compliance with pharmaceutical standards for
7 identity, strength, quality, and purity of the compounded drug that
8 are consistent with United States Pharmacopoeia guidelines and
9 accreditation practices.

10 Sec. 562.152. COMPOUNDING FOR OFFICE USE. A pharmacy may
11 dispense and deliver a reasonable quantity of a compounded drug to a
12 practitioner for office use by the practitioner in accordance with
13 this chapter.

14 Sec. 562.153. REQUIREMENTS FOR OFFICE USE COMPOUNDING. To
15 dispense and deliver a compounded drug under Section 562.152, a
16 pharmacy must:

17 (1) verify the source of the raw materials to be used
18 in a compounded drug;

19 (2) comply with applicable United States
20 Pharmacopoeia guidelines, including the testing requirements, and
21 the Health Insurance Portability and Accountability Act of 1996
22 (Pub. L. No. 104-191);

23 (3) comply with all applicable competency and
24 accrediting standards as determined by the board; and

25 (4) comply with board rules, including rules regarding
26 the reporting of adverse events by practitioners and recall
27 procedures for compounded products.

1 Sec. 562.154. DISTRIBUTION OF COMPOUNDED AND PREPACKAGED
2 PRODUCTS TO CERTAIN PHARMACIES. (a) A Class A pharmacy licensed
3 under Chapter 560 is not required to register or be licensed under
4 Chapter 431, Health and Safety Code, to distribute compounded
5 pharmaceutical products to a Class C pharmacy licensed under
6 Chapter 560.

7 (b) A Class C pharmacy licensed under Chapter 560 is not
8 required to register or be licensed under Chapter 431, Health and
9 Safety Code, to distribute compounded and prepackaged
10 pharmaceutical products that the Class C pharmacy has compounded or
11 prepackaged to other Class C pharmacies licensed under Chapter 560
12 and under common ownership.

13 Sec. 562.155. COMPOUNDING SERVICE AND COMPOUNDED DRUG
14 PRODUCTS. A compounding pharmacist or pharmacy may advertise or
15 promote:

16 (1) nonsterile prescription compounding services
17 provided by the pharmacist or pharmacy; and

18 (2) specific compounded drug products that the
19 pharmacy or pharmacist dispenses or delivers.

20 SECTION 5. Subdivision (23), Section 431.002, Health and
21 Safety Code, is amended to read as follows:

22 (23) "Manufacture" means:

23 (A) the process of combining or purifying food or
24 packaging food for sale to a person at wholesale or retail, and
25 includes repackaging, labeling, or relabeling of any food;

26 (B) the process of preparing, propagating,
27 compounding, processing, packaging, repackaging, labeling,

1 testing, or quality control of a drug or drug product, but does not
2 include compounding that is done within the practice of pharmacy
3 and pursuant to a prescription drug order or initiative from a
4 practitioner for a patient or prepackaging that is done in
5 accordance with Section 562.154, Occupations Code;

6 (C) the process of preparing, fabricating,
7 assembling, processing, packing, repacking, labeling, or
8 relabeling a device; or

9 (D) the making of any cosmetic product by
10 chemical, physical, biological, or other procedures, including
11 manipulation, sampling, testing, or control procedures applied to
12 the product.

13 SECTION 6. Subsection (a), Section 431.2021, Health and
14 Safety Code, is amended to read as follows:

15 (a) A person who engages in wholesale distribution of
16 prescription drugs in this state for use in humans is exempt from
17 this subchapter if the person is exempt under:

18 (1) the Prescription Drug Marketing Act of 1987, as
19 amended (21 U.S.C. Section 353(c)(3)(B));

20 (2) the regulations adopted by the secretary to
21 administer and enforce that Act; [~~or~~]

22 (3) the interpretations of that Act set out in the
23 compliance policy manual of the United States Food and Drug
24 Administration; or

25 (4) Section 562.154, Occupations Code.

26 SECTION 7. This Act takes effect September 1, 2005.

David Sunkunst
President of the Senate

[Signature]
Speaker of the House

I hereby certify that S.B. No. 492 passed the Senate on April 7, 2005, by the following vote: Yeas 31, Nays 0.

[Signature]
Secretary of the Senate

I hereby certify that S.B. No. 492 passed the House on April 28, 2005, by a non-record vote.

[Signature]
Chief Clerk of the House

Approved:

9 MAY '05
Date

[Signature]
Governor

FILED IN THE OFFICE OF THE
SECRETARY OF STATE
6 PM O'CLOCK

[Signature]
Secretary of State